GLP-1/FGF21 agonist
Phase 1
Therapeutic Area: Cardiometabolic Diseases
Anchored in external partnership or acquisition
This compound is under investigation, further information will be available soon.
Phase 1
Therapeutic Area: Cardiometabolic Diseases
Anchored in external partnership or acquisition
This compound is under investigation, further information will be available soon.